FL
ALXN

Fort LP’s Alexion Pharmaceuticals ALXN Stock Holding History

Fort LP’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,813
Closed -$1.44M – 294
2021
Q2 		$1.44M Sell
7,813
-4,156
-35% -$713K 0.41% 139
2021
Q1 		$1.83M Buy
11,969
+1,593
+15% +$246K 0.51% 73
2020
Q4 		$1.62M Buy
10,376
+5,745
+124% +$738K 0.48% 102
2020
Q3 		$530K Buy
+4,631
New +$500K 0.22% 199

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Fort LP's ALXN Position: Q3 2021 in Review

Fort LP sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 7,813 shares — an estimated $1.44M sold.

Fort LP first reported a position in ALXN in Q3 2020 and held it in 4 quarters. The position peaked at $1.83M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Fort LP reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Fort LP sold 7,813 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.44M.
  • Fort LP first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Fort LP's Alexion Pharmaceuticals position peaked at $1.83M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Fort LP's 13F filing for Q3 2021, filed 12 Nov 2021.